Tevogen (TVGN) Operating Expenses (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Operating Expenses came in at $5.4 million in Q1 2026, down 47.85% YoY from $10.4 million in Q1 2025, and up 17.15% on a QoQ basis from $4.6 million in Q4 2025.
Tevogen (TVGN) Operating Expenses (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Operating Expenses data on file, last reported at $5.4 million in Q1 2026.
- Quarterly Operating Expenses fell 47.85% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (down 38.42% YoY) and the FY2025 annual result came in at $26.1 million, down 51.2% from the prior year.
- Operating Expenses advanced to $5.4 million in Q1 2026, from $4.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $29.5 million in Q1 2024 to a low of $198832.0 in Q3 2022.
- A 5-year average of $5.6 million and a median of $4.6 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 1169.93% — and 2025, when it slumped 64.91%.
- Tracing TVGN's Operating Expenses over 5 years: stood at $212787.0 in 2022, then jumped by 844.26% to $2.0 million in 2023, then soared by 366.0% to $9.4 million in 2024, then tumbled by 50.76% to $4.6 million in 2025, then grew by 17.15% to $5.4 million in 2026.
- The last three Operating Expenses figures came in at $5.4 million (Q1 2026), $4.6 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 541.02 Mn |
| 10 | Tevogen | 25.73 Mn | 25.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.40 Mn |
| Dec 31, 2025 | 4.61 Mn |
| Sep 30, 2025 | 5.73 Mn |
| Jun 30, 2025 | 5.44 Mn |
| Mar 31, 2025 | 10.36 Mn |
| Dec 31, 2024 | 9.36 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 8.60 Mn |
| Mar 31, 2024 | 29.52 Mn |
| Dec 31, 2023 | 2.01 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.18 Mn |
| Mar 31, 2023 | 2.32 Mn |
| Dec 31, 2022 | 212,787.00 |
| Sep 30, 2022 | 198,832.00 |
| Jun 30, 2022 | 258,585.00 |
| Mar 31, 2022 | 282,879.00 |